期刊文献+
共找到1,598篇文章
< 1 2 80 >
每页显示 20 50 100
Milk-derived exosomes as a promising vehicle for oral delivery of hydrophilic biomacromolecule drugs 被引量:3
1
作者 Yuting Li Liyun Xing +7 位作者 Lingling Wang Xi Liu Licheng Wu Mingjie Ni Zhou Zhou Lian Li Xiuxiu Liu Yuan Huang 《Asian Journal of Pharmaceutical Sciences》 SCIE CAS 2023年第2期137-149,共13页
Exosomes,as promising vehicles,have been widely used in the research of oral drug delivery,but the generally low drug loading efficiency of exosomes seriously limits its application and transformation.In this study,we... Exosomes,as promising vehicles,have been widely used in the research of oral drug delivery,but the generally low drug loading efficiency of exosomes seriously limits its application and transformation.In this study,we systematically investigated the effects of drug loading methods and physicochemical properties(lipophilicity and molecular weight)on drug loading efficiency of milk-derived exosomes to explore the most appropriate loading conditions.Our finding revealed that the drug loading efficiency of exosomes was closely related to the drug loading method,drug lipophilicity,drug molecular weight and exosome/drug proportions.Of note,we demonstrated the universality that hydrophilic biomacromolecule drugs were the most appropriate loading drugs for milk-derived exosomes,which was attributed to the efficient loading capacity and sustained release behavior.Furthermore,milk-derived exosomes could significantly improve the transepithelial transport and oral bioavailability of model hydrophilic biomacromolecule drugs(octreotide,exendin-4 and salmon calcitonin).Collectively,our results suggested that the encapsulation of hydrophilic biomacromolecule drugs might be the most promising direction for milk exosomes as oral drug delivery vehicles. 展开更多
关键词 Milk-derived exosomes Loading efficiency drug lipophilicity Molecular weight drug release oral delivery
下载PDF
Effects of anti-diabetic drugs on sarcopenia: Best treatment options for elderly patients with type 2 diabetes mellitus and sarcopenia 被引量:1
2
作者 Xiao-Yu Ma Fen-Qin Chen 《World Journal of Clinical Cases》 SCIE 2021年第33期10064-10074,共11页
Human life expectancy increases as society becomes more developed.This increased life expectancy poses challenges associated with the rapid aging of the population.Sarcopenia,an age-related disease,has become a worldw... Human life expectancy increases as society becomes more developed.This increased life expectancy poses challenges associated with the rapid aging of the population.Sarcopenia,an age-related disease,has become a worldwide health issue.Patients with sarcopenia experience decreases in muscle mass and function,becoming frail and eventually bedridden.Type 2 diabetes mellitus(T2DM)is also a major health issue;the incidence of T2DM increases with aging.T2DM is associated with reduced muscle strength and poor muscle quality and may contribute to acceleration of the aging process,augmenting age-related sarcopenia.Recent studies indicate that elderly patients with diabetes are at an increased risk for sarcopenia.Therefore,these older diabetic patients with sarcopenia need specific anti-diabetic therapies targeting not only glycemic control but also sarcopenia,with the goal of preventing sarcopenia in presarcopenic patients.Presently,various types of hypoglycemic drugs are available,but which hypoglycemic drugs are better suited for geriatric T2DM patients with sarcopenia remains undetermined.In this review,we discuss the association between diabetes and sarcopenia in geriatric patients,and how anti-diabetic drugs may influence sarcopenia outcomes.This review will guide clinical workers in the selection of drugs best suited for this patient population. 展开更多
关键词 Type 2 diabetes mellitus SARCOPENIA anti-diabetic drugs GERIATRIC
下载PDF
Causative anti-diabetic drugs and the underlying clinical factors for hypoglycemia in patients with diabetes 被引量:3
3
作者 Hidekatsu Yanai Hiroki Adachi +3 位作者 Hisayuki Katsuyama Sumie Moriyama Hidetaka Hamasaki Akahito Sako 《World Journal of Diabetes》 SCIE CAS 2015年第1期30-36,共7页
Recent clinical trials indicated that the intensive glycemic control do not reduce cardiovascular disease mortality among diabetic patients, challenging a significance of the strict glycemic control in diabetes manage... Recent clinical trials indicated that the intensive glycemic control do not reduce cardiovascular disease mortality among diabetic patients, challenging a significance of the strict glycemic control in diabetes management. Furthermore, retrospective analysis of the Action to Control Cardiovascular Risk in Diabetes study demonstrated a significant association betweenhypoglycemia and mortality. Here, we systematically reviewed the drug-induced hypoglycemia, and also the underlying clinical factors for hypoglycemia in patients with diabetes. The sulfonylurea use is significantly associated with severe hypoglycemia in patients with type 2 diabetes. The use of biguanide(approximately 45%-76%) and thiazolidinediones(approximately 15%-34%) are also highly associated with the development of severe hypoglycemia. In patients treated with insulin, the intensified insulin therapy is more frequently associated with severe hypoglycemia than the conventional insulin therapy and continuous subcutaneous insulin infusion. Among the underlying clinical factors for development of severe hypoglycemia, low socioeconomic status, aging, longer duration of diabetes, high Hb A1 c and low body mass index, comorbidities are precipitating factors for severe hypoglycemia. Poor cognitive and mental functions are also associated with severe hypoglycemia. 展开更多
关键词 COMORBIDITY HYPOGLYCEMIA INSULIN oralanti-diabetic drugs
下载PDF
The neuroprotective effects of the anti-diabetic drug linagliptin against Aβ-induced neurotoxicity 被引量:2
4
作者 Chih-Li Lin Chien-Ning Huang 《Neural Regeneration Research》 SCIE CAS CSCD 2016年第2期236-237,共2页
Impaired insulin signaling in Alzheimer’s disease(AD)brains:The insulin signaling pathway is a fundamental physiological mechanism that presents in nearly all vertebrate cells.However,sometimes cells stop respondi... Impaired insulin signaling in Alzheimer’s disease(AD)brains:The insulin signaling pathway is a fundamental physiological mechanism that presents in nearly all vertebrate cells.However,sometimes cells stop responding properly to insulin stimulation.This condition is known as insulin resistance,which is a hallmark of two very common conditions,metabolic syndrome and type 2 diabetes(T2D). 展开更多
关键词 GLP induced neurotoxicity DPP The neuroprotective effects of the anti-diabetic drug linagliptin against A AMPK
下载PDF
Preparation of Ionic Liquid Functionalized Silica Nanoparticles for Oral Drug Delivery 被引量:3
5
作者 Mehrdad Mahkam Fatemeh Hosseinzadeh Mohammad Galehassadi 《Journal of Biomaterials and Nanobiotechnology》 2012年第3期391-395,共5页
The objective of this study is to utilize the pH sensitivity of modified silica nanoparticles (SNIL) by imidazole-based ionic liquid for oral delivery of insulin. In the first time, the imidazole was covalently attach... The objective of this study is to utilize the pH sensitivity of modified silica nanoparticles (SNIL) by imidazole-based ionic liquid for oral delivery of insulin. In the first time, the imidazole was covalently attached to the 3-trimethoxysily-lpropyl chloride with replacement of all the chlorine atoms. Then, a silica nanoparticle was modified by N-(3-trimeth-oxysilylpropyl) imidazole. The nanocapsule (NCIL) was achieved after the etching of the modified silica nanoparticle template with hydrofluoric acid. The nanoparticles connected through an ionic liquid-like network were characterized by FTIR and SEM. Insulin was entrapped in these carriers and the in vitro release profiles were established separately in both enzyme-free simulated gastric and intestinal fluids (SGF, pH 1) and (SIF, pH 7.4), respectively. When these drug-loaded nanoparticles was placed in physiological buffer solution (pH 7.4), a partial negative surface charge on the modified silica nanoparticle was generated due to the deprotonation of silanol groups, and the strong electrostatic repulsion triggered a sustained release of the loaded molecules. 展开更多
关键词 Silica Nanoparticles NANOCAPSULE PH-SENSITIVE INSULIN oral drug Delivery
下载PDF
UNIQUE ORAL DRUG DELIVERY SYSTEM 被引量:1
6
作者 Raphael M.Ottenbrite Sam Milstein 《Chinese Journal of Polymer Science》 SCIE CAS CSCD 1995年第4期315-321,共7页
An oral drug delivery system using proteinoid microspheres is discussed with respect to itsunique dependence on pH. It has been found that certain drugs such as insulin and heparin canbe encapsulated in proteinoid sph... An oral drug delivery system using proteinoid microspheres is discussed with respect to itsunique dependence on pH. It has been found that certain drugs such as insulin and heparin canbe encapsulated in proteinoid spheres at stomach pH's (1--3). These spheres also dissemble atintestinal pH's (6--7) releasing the drug for absorption. Using this technique low molecularweight heparin and human growth hormone have been orally delivered successfully to severalanimal species. Future work has been proposed to study the interaction and binding of thespecific drugs with synthesized oligopeptides. 展开更多
关键词 oral drug delivery system Proteinoid microspheres OLIGOPEPTIDES
下载PDF
From oral formulations to drug-eluting implants:using 3D and 4D printing to develop drug delivery systems and personalized medicine 被引量:2
7
作者 Niels G.A.Willemen Margaretha A.J.Morsink +4 位作者 Devin Veerman Classius F.da Silva Juliana C.Cardoso Eliana B.Souto Patrícia Severino 《Bio-Design and Manufacturing》 SCIE EI CAS CSCD 2022年第1期85-106,共22页
Since the start of the Precision Medicine Initiative by the United States of America in 2015,interest in personalized medicine has grown extensively.In short,personalized medicine is a term that describes medical trea... Since the start of the Precision Medicine Initiative by the United States of America in 2015,interest in personalized medicine has grown extensively.In short,personalized medicine is a term that describes medical treatment that is tuned to the individual.One possible way to realize personalized medicine is 3D printing.When using materials that can be tuned upon stimulation,4D printing is established.In recent years,many studies have been exploring a new field that combines 3D and 4D printing with therapeutics.This has resulted in many concepts of pharmaceutical devices and formulations that can be printed and,possibly,tailored to an individual.Moreover,the first 3D printed drug,Spritam®,has already found its way to the clinic.This review gives an overview of various 3D and 4D printing techniques and their applications in the pharmaceutical field as drug delivery systems and personalized medicine. 展开更多
关键词 drug delivery systems 3D/4D printing drug-eluting implants MICRONEEDLES oral formulations
下载PDF
A Critical Review on Traditional Herbal Drugs: An Emerging Alternative Drug for Diabetes
8
作者 Krishna Bihari Pandeya Indra Prasad Tripathi +6 位作者 Mahendra Kumar Mishra Neelesh Dwivedi Yogesh Pardhi Arti Kamal Priyanka Gupta Nupa Dwivedi Chinmayi Mishra 《International Journal of Organic Chemistry》 2013年第1期1-22,共22页
Diabetes is a chronic metabolic disease reaching an epidemic proportion in many parts of the world. By the year 2025 it is expected that 333 million people of the world will have diabetes as their main ailment. As tod... Diabetes is a chronic metabolic disease reaching an epidemic proportion in many parts of the world. By the year 2025 it is expected that 333 million people of the world will have diabetes as their main ailment. As today, India assumes the position of the diabetic capital of the world with the highest percentage of its population suffering from diabetes. It is pathetic to mention that in proportion to its people suffering from diabetes, this country has very weak spending power for treatment because of wide spread poverty. Therefore, this review is aimed at opening up new vistas in realizing the therapeutic potential of Ayurveda in treatment of diabetes and other chronic diseases. All drugs which we have discussed in this review have a significant role in therapy of diabetes mellitus. 展开更多
关键词 DIABETES Mellitus Metabolic Disease AYURVEDA HYPERGLYCEMIA Synthetic drugs HERBAL drugs Metallo Therapy oral HYPOGLYCEMIC drugs
下载PDF
Comparison of drug concentrations in blood and gastric lavage fluid before and after gastric lavage:A case report 被引量:1
9
作者 Yue Zhou Jia-Le Tong +1 位作者 Ai-Hua Peng Shu-Yun Xu 《World Journal of Clinical Cases》 SCIE 2023年第31期7680-7683,共4页
BACKGROUND Gastric lavage(GL)is one of the most important early therapies to remove unabsorbed toxins from the gastrointestinal tract.However,the details of performing gastric lavage remain to be established.There is ... BACKGROUND Gastric lavage(GL)is one of the most important early therapies to remove unabsorbed toxins from the gastrointestinal tract.However,the details of performing gastric lavage remain to be established.There is controversy in clinical practice regarding individual choice of the timing of GL and its efficiency.CASE SUMMARY We report the case of a young woman who presented to the Emergency Department with drug intoxication for four hours.We used the latest toxicological screening techniques to compare drug concentrations in the patient's blood and gastric lavage fluid before and after gastric lavage.The results confirmed that gastric lavage was effective in reducing drug concentrations in the stomach;a small amount of drug remained in the stomach at the end of gastric lavage.CONCLUSION Gastric lavage is effective in reducing drug concentrations in the stomach,with a small amount of drug remaining in the stomach at the end of gastric lavage. 展开更多
关键词 Gastric lavage drug concentrations oral poisoning Case report
下载PDF
Comparative Review of Drugs Used in Diabetes Mellitus—New and Old
10
作者 Furqan Ul Haq Abuzar Siraj +5 位作者 Muhammad Atif Ameer Tanveer Hamid Mansoor Rahman Salman Khan Saad Khan Sarwat Masud 《Journal of Diabetes Mellitus》 2021年第4期115-131,共17页
<strong>Background:</strong> Diabetes mellitus (DM) is a syndrome of chronically elevated glucose level in the blood either due to insulin resistance, insulin deficiency or both. In addition, it may occur ... <strong>Background:</strong> Diabetes mellitus (DM) is a syndrome of chronically elevated glucose level in the blood either due to insulin resistance, insulin deficiency or both. In addition, it may occur due to defective metabolism of carbohydrates, fats and proteins. There are 3 main types of DM: Type 2 DM is more prevalent in adults and is typically due to relative insulin deficiency, deficiency of insulin in children leads to DM type 1;and lastly, gestational diabetes occurs during pregnancy resulting from an imbalance of placental hormones. <strong>Introduction:</strong> Insulin, Biguanides and Sulfonylureas are some of the drug classes used to treat DM. However, their use is complicated by numerous side effects, such as;hypoglycemia & weight gain from insulin and sulfonylureas;lactic acidosis, vitamin B12 deficiency and gastrointestinal upset with metformin. Route of administration and cost are also important factors to consider when prescribing. It is for this reason the quest for newer, safer and easier to administer drugs is ongoing. <strong>Methodology:</strong> Used all the articles available on anti Diabetic drugs on web especially in British Medical Journal, Elsevier, Pubmed, Google scholar and Wikipedia etc. Got a final review article to compare the older and newer anti Diabetic drugs. <strong>Results and Conclusion:</strong> Insulin is good for controlling acute hyperglycemic states in DM but it causes acute hypoglycemia and lipodystrophy. Metformin is good hypoglycemic and easily available but causes hypoglycemia, metallic taste, Lactic acidosis and B12 deficiency. Sulfonylureas are good hypoglycemic but causes severe hypoglycemia acutely and weight gain so contraindicated for obese or hypertensive patients. While newer antidiabetics such as GLP 1 agonists increases insulin secretions has very low risk of hypoglycemia, causes weight loss as compared to insulin and decreases risk of cardiovascular side effects but still can’t be used in renally impaired patients, causes pancreatitis and can not be given in gastroparesis patients, similarly a newer drug of this class known as LY2189265 has long halflife of 90 hours, better efficacy, but causes pancreatitis and increase diastolic BP in high doses, pancreatitis is not associated with lixisenatide (GLP 1 agonist), while DPP4 inhibitors which increases GLP 1 in body has less risk of hypoglycemia, GI side effects, are weight neutral can be used in CKD but causes headaches and Nasopharyngitis. Bromocriptine or pegvisomant are used in patients of growth hormones adenoma induced DM as a medical therapy but are associated with psychosis and hallucinations. Meglitinides increases insulin secretion and has minuscule risk of hypoglycemia but can not be used in CKD patients. Otelixizumab and Teplizumab decrease T cell functions and save beta cells from immune reactions used in DM 1 but cause immune suppression and is an orphan drug. Recombinant GAD used in vaccines decreased antibody mediated beta cell damage but is still under studies. 展开更多
关键词 anti-diabetic drugs METFORMIN SITAGLIPTIN Canagliflozin EXENATIDE PIOGLITAZONE Insulin Use and Its Efficacy GLIPIZIDE
下载PDF
Liver injury from direct oral anticoagulants
11
作者 Deven Juneja Prashant Nasa Ravi Jain 《World Journal of Hepatology》 2023年第6期841-849,共9页
BACKGROUND Drug-induced liver injury(DILI)can be caused by any prescribed drug and is a significant reason for the withdrawal of newly launched drugs.Direct-acting oral anticoagulants(DOACs)are non-vitamin K-based ant... BACKGROUND Drug-induced liver injury(DILI)can be caused by any prescribed drug and is a significant reason for the withdrawal of newly launched drugs.Direct-acting oral anticoagulants(DOACs)are non-vitamin K-based antagonists recently introduced and increasingly used for various clinical conditions.A meta-analysis of 29 randomised controlled trials and 152116 patients reported no increased risk of DILI with DOACs.However,it is challenging to predict the risk factors for DILI in individual patients with exclusion of patients with pre-existing liver disease from these studies.AIM To determine the risk factors and outcomes of patients who developed DILI secondary to DOACs by systematic review and meta-summary of recent case reports and series.METHODS A systematic search was conducted on multiple databases including PubMed,Science Direct,Reference Citation Analysis,and Google Scholar.The search terms included“Acute Liver Failure”OR“Acute-On-Chronic Liver Failure”OR“Acute Chemical and Drug Induced Liver Injury”OR“Chronic Chemical and Drug Induced Liver Injury”AND“Factor Xa Inhibitors”OR“Dabigatran”OR“Rivaroxaban”OR“apixaban”OR“betrixaban”OR“edoxaban”OR“Otamixaban”.The results were filtered for literature published in English and on adult patients.Only case reports and case studies reporting cases of DILI secondary to DOACs were included.Data on demographics,comorbidities,medication history,laboratory investigations,imaging,histology,management,and outcomes were extracted.RESULTS A total of 15 studies(13 case reports and 2 case series)were included in the analysis,comprising 27 patients who developed DILI secondary to DOACs.Rivaroxaban was the most commonly implicated DOAC(n=20,74.1%).The mean time to onset of DILI was 40.6 d.The most common symptoms were jaundice(n=15,55.6%),malaise(n=9,33.3%),and vomiting(n=9,33.3%).Laboratory investigations showed elevated liver enzymes and bilirubin levels.Imaging studies and liver biopsies revealed features of acute hepatitis and cholestatic injury.Most patients had a favourable outcome,and only 1 patient(3.7%)died due to liver failure.CONCLUSION DOACs are increasingly used for various clinical conditions,and DILI secondary to DOACs is a rare but potentially serious complication.Prompt identification and cessation of the offending drug are crucial for the management of DILI.Most patients with DILI secondary to DOACs have a favourable outcome,but a small proportion may progress to liver failure and death.Further research,including post-marketing population-based studies,is needed to better understand the incidence and risk factors for DILI secondary to DOACs. 展开更多
关键词 ANTICOAGULANTS Direct-acting oral anticoagulants drug induced liver injury drug reactions HEPATOTOXICITY Novel oral anticoagulants
下载PDF
Drug utilization analysis of oral hypoglycemic agents in our hospital during the period of 2003~2005
12
作者 辛海莉 《药学实践杂志》 CAS 2007年第6期393-395,共3页
关键词 口服降血糖药 药效 规定日剂量 糖尿病 合理用药
下载PDF
创新软件和设备在口服外摆拆零药品智能化管理中的应用
13
作者 陈洁 陈婷 +3 位作者 王立华 何丽娜 姜赛平 吴军 《中国处方药》 2024年第10期62-66,共5页
目的通过开发智能创新软件结合独立调配桌对住院药房口服外摆拆零药品进行高效、安全的管理和调配,确保药品的安全供应。方法设置独立外摆药品调配操作台,利用创新软件集成掌上电脑(PDA)智能系统,结合条码扫描导入技术与全自动药品分包... 目的通过开发智能创新软件结合独立调配桌对住院药房口服外摆拆零药品进行高效、安全的管理和调配,确保药品的安全供应。方法设置独立外摆药品调配操作台,利用创新软件集成掌上电脑(PDA)智能系统,结合条码扫描导入技术与全自动药品分包机,优化和改进口服外摆药品调剂、加药、有效期维护等易错环节。对比创新软件使用前后口服医嘱平均调剂时长(min),外摆拆零药品月均盘存时长(min)和外摆拆零药品有效期维护平均时长(min)。结果使用创新软件和设备后,口服医嘱平均调剂时长从(218.07±6.72)min缩短至(173.81±6.08)min(P<0.01),均值减少44.26 min;外摆拆零药品月均盘存时长从(156.00±5.29)min缩短至(108.00±2.64)min(P<0.01),均值缩短48.00 min;外摆拆零药品有效期维护平均时长从(147.00±2.64)min缩短至(23.00±3.00)min(P<0.01),均值缩短124 min。结论该项创新应用可解决传统外摆拆零药品容易出现的药品混装、定位混乱、库存数量不明、效期管理困难等问题,实现了药品管理的精细化、科学化,有效提高了药师的工作效率和服务质量,同时也为患者提供了更加安全、便捷的用药服务。 展开更多
关键词 创新软件 独立外摆药品调配操作台 口服外摆拆零药品 智慧药房
下载PDF
大黄三味片治疗抗精神病药药物性便秘临床观察
14
作者 刘博 《中国医药指南》 2024年第5期121-123,共3页
目的探讨大黄三味片治疗抗精神病药药物性便秘的有效性和安全性。方法收集2020年7月至2022年12月沈阳市精神科卫生中心精神科病房符合抗精神病药药物性便秘诊断标准的120例患者,按照随机数字法分为治疗组和对照组,每组60例,治疗组予大... 目的探讨大黄三味片治疗抗精神病药药物性便秘的有效性和安全性。方法收集2020年7月至2022年12月沈阳市精神科卫生中心精神科病房符合抗精神病药药物性便秘诊断标准的120例患者,按照随机数字法分为治疗组和对照组,每组60例,治疗组予大黄三味片治疗,对照组予乳果糖口服溶液。观察两组患者治疗前后便秘症状积分,排便时间,腹痛评分(VAS),大便性状改善时间、停药7 d内排便次数及生活质量评分。结果两组治疗有效率对比无统计学差异(P>0.05);治疗组大便性状改善时间短于对照组、停药7 d的排便次数多于对照组(均P<0.05);治疗后,治疗组便秘症状评分、腹痛评分、排便时间低于对照组,生活质量评分高于对照组(均P<0.05)。结论大黄三味片治疗抗精神病药药物性便秘临床疗效确切,有效减轻患者痛苦,停药后疗效持久,两组患者均未见不良反应,安全有效。 展开更多
关键词 大黄三味片 抗精神病药药物性便秘 乳果糖口服溶液
下载PDF
表观遗传药物联合诱导口腔癌FMR1NB表达的研究
15
作者 张煜萱 谢欢 +8 位作者 王燕靖 李枫 王国鉴 农蔚霞 刘畅 罗彬 谢小薰 沈宁 张庆梅 《安徽医科大学学报》 CAS 北大核心 2024年第5期761-766,共6页
目的研究DNA去甲基化药物联合组蛋白去乙酰化酶抑制剂对人口腔癌细胞脆性X智障基因1邻近蛋白(FMR1NB)表达及其启动子甲基化的影响,探寻改善FMR1NB表达异质性的方法和策略。方法DNA甲基化转移酶抑制剂地西他滨(DAC)联合组蛋白去乙酰化酶... 目的研究DNA去甲基化药物联合组蛋白去乙酰化酶抑制剂对人口腔癌细胞脆性X智障基因1邻近蛋白(FMR1NB)表达及其启动子甲基化的影响,探寻改善FMR1NB表达异质性的方法和策略。方法DNA甲基化转移酶抑制剂地西他滨(DAC)联合组蛋白去乙酰化酶抑制剂曲古抑菌素A(TSA)和丙戊酸(VPA)干预人舌鳞癌细胞株Cal27和SCC-9后,采用逆转录-聚合酶链式反应(RT-PCR)、实时定量RT-PCR(qRT-PCR)和蛋白印迹法(Western blot)检测干预前后FMR1NB的表达变化;焦磷酸测序法检测干预前后FMR1NB启动子甲基化的变化。结果与空白对照组相比,DAC及其与TSA和VPA联合组均能显著诱导Cal27和SCC-9中FMR1NB mRNA和蛋白的表达。与DAC单独组比较,Cal27中各联合用药组的FMR1NB mRNA表达水平均显著升高,但FMR1NB蛋白表达无明显变化;而SCC-9中除DAC与TSA联合组不能明显提升FMR1NB mRNA表达水平之外,其余各组均能引起FMR1NB mRNA和蛋白水平的显著升高。此外,两株细胞中FMR1NB mRNA和蛋白表达在三药联合组和各两药联合组之间差异均无统计学意义。进一步甲基化测定显示:除SCC-9的三药联合组之外,其余各给药组在两株细胞中FMR1NB启动子区的整体甲基化水平和所测各CpG位点的甲基化水平均有不同程度地降低。结论DAC及其TSA和VPA联合组普遍可介导FMR1NB启动子去甲基化而增强FMR1NB表达,其中两药联合组的增强表达作用更强。 展开更多
关键词 口腔癌 FMR1NB 表观遗传学药物 表达 甲基化
下载PDF
新型口服抗凝剂治疗癌症患者静脉血栓栓塞有效性及安全性的Meta分析 被引量:1
16
作者 王祖秀 李旭欢 +4 位作者 尤培蒙 朱挺德 陈黎旭 燕肄群 潘永平 《中国药房》 CAS 北大核心 2024年第7期842-847,共6页
目的系统评价癌症相关静脉血栓栓塞(VTE)患者使用新型口服抗凝剂(NOAC)的有效性和安全性。方法检索PubMed、Cochrane Library、Embase、Web of Science、中国知网、万方数据库,检索时限为各数据库建库起至2023年8月,收集低分子肝素(LMWH... 目的系统评价癌症相关静脉血栓栓塞(VTE)患者使用新型口服抗凝剂(NOAC)的有效性和安全性。方法检索PubMed、Cochrane Library、Embase、Web of Science、中国知网、万方数据库,检索时限为各数据库建库起至2023年8月,收集低分子肝素(LMWH,对照组)对比NOAC(试验组)治疗癌症相关VTE患者疗效的随机对照试验(RCT),对纳入临床研究进行资料提取后,采用RevMan 5.0统计软件进行Meta分析。结果共计纳入7项RCT,合计3790例癌症相关VTE患者。与对照组相比,试验组患者的VTE复发率(RR=0.65,95%CI为0.51~0.82,P=0.0004)显著降低,而其大出血发生率略高于对照组,但差异无统计学意义(RR=1.13,95%CI为0.83~1.53,P=0.45)。试验组患者的临床相关非主要大出血(RR=1.69,95%CI为1.34~2.13,P<0.00001)、消化道出血(RR=1.96,95%CI为1.15~3.34,P=0.01)发生率均较对照组显著升高。两组患者颅内出血发生率、全因死亡率、致死性肺栓塞发生率比较,差异均无统计学意义(P>0.05)。结论对于癌症相关VTE患者,NOAC在预防VTE复发方面优于LMWH,在大出血、颅内出血、全因死亡、致死性肺栓塞方面不劣于LMWH。 展开更多
关键词 癌症 静脉血栓栓塞 抗凝药 低分子肝素 新型口服抗凝剂
下载PDF
口腔苔藓样药物反应的研究进展
17
作者 黎希晔 葛姝云 唐国瑶 《口腔疾病防治》 2024年第7期555-561,共7页
口腔苔藓样药物反应(oral lichenoid drug reactions,OLDR)是特殊体质者使用特定药物后引起的口腔黏膜炎性反应,属于口腔苔藓样损害(oral lichenoid lesions,OLL)这一病种,其临床表现和病理表现与其他种类的OLL相比不存在明显的特异性,... 口腔苔藓样药物反应(oral lichenoid drug reactions,OLDR)是特殊体质者使用特定药物后引起的口腔黏膜炎性反应,属于口腔苔藓样损害(oral lichenoid lesions,OLL)这一病种,其临床表现和病理表现与其他种类的OLL相比不存在明显的特异性,可能诱发OLDR的药物种类繁多,包括了降压药、非甾体抗炎药、降糖药、抗焦虑/精神类药物、生物制剂等,治疗方案除局部或全身使用糖皮质激素以外,停用可疑药物是最有效的治疗措施,大多数患者的黏膜溃疡、糜烂能得到较大缓解,但可能仍有白纹残留。虽然OLDR已在文献报道和临床工作中得到广泛关注,但由于缺乏系统的认识,对于OLDR的诊断并没有公认的标准,也缺乏规范化的诊疗流程,且相关药物与口腔苔藓样病变之间的因果关系仍然存在疑问。针对以上问题,笔者检索了近20年国内外药物相关口腔扁平苔藓和苔藓样损害的文献,其中绝大多数为病例报告,仅有少量病例对照研究。本文从相关概念、可疑药物、临床及病理表现、治疗预后4个方面介绍了其研究现状,希望能为相关苔藓样损害的预防、诊断和临床治疗提供理论参考。文献综述显示了该疾病在病因、发病机制、临床诊疗、治疗预后等方面仍有大量问题尚不明确,仍需进一步开展临床及基础研究予以深入探索。 展开更多
关键词 口腔扁平苔藓 口腔苔藓样药物反应 苔藓样反应 苔藓样疹 降压药 非甾体类抗炎药 降糖药 免疫抑制剂
下载PDF
儿童苔藓样肉芽肿性口炎1例报道及文献回顾
18
作者 徐婧 夏荣辉 +2 位作者 杨涟漪 沈雪敏 杜观环 《口腔疾病防治》 2024年第2期137-142,共6页
目的探讨口腔苔藓样损害的分类、临床表现、诊断、鉴别诊断及治疗,为临床提供参考。方法获得医院伦理审批及患者知情同意,报道1例儿童口腔苔藓样损害病例,结合文献对口腔苔藓样损害的诊疗进行回顾分析。结果患儿舌背反复破溃伴疼痛3年余... 目的探讨口腔苔藓样损害的分类、临床表现、诊断、鉴别诊断及治疗,为临床提供参考。方法获得医院伦理审批及患者知情同意,报道1例儿童口腔苔藓样损害病例,结合文献对口腔苔藓样损害的诊疗进行回顾分析。结果患儿舌背反复破溃伴疼痛3年余,舌背大面积糜烂面,形状不规则,糜烂周围见珠光白色纹,左侧糜烂区伴组织增生,约1.5 cm×2.0 cm,质地韧,宽蒂。舌背白色网纹组织切取活检病理诊断为苔藓样损害;舌背增生物切除活检病理诊断为苔藓样损害伴肉芽肿性炎。根据患者口内损害特征、系统病史、用药史、组织病理学检查结果,最终诊断为苔藓样肉芽肿性口炎。文献回顾表明,口腔苔藓样损害病因不明,临床上需与口腔扁平苔藓、口腔苔藓样药物反应、口腔苔藓样接触性损害、慢性溃疡性口炎等疾病鉴别。临床上治疗口腔苔藓样损害以糖皮质激素的局部和/或全身使用为主。结论目前口腔苔藓样损害的分类和诊断仍无统一标准,主要依靠病史询问、临床表现和组织病理学检查结果,治疗方法主要为糖皮质激素的局部和/或全身使用。 展开更多
关键词 口腔苔藓样损害 苔藓样肉芽肿性口炎 口腔扁平苔藓 口腔苔藓样药物反应 口腔苔藓样接触性损害 移植物抗宿主病相关性苔藓样损害 慢性溃疡性口炎 类天疱疮样扁平苔藓 儿童 糖皮质激素
下载PDF
左心室血栓患者抗栓治疗的单中心回顾性分析
19
作者 齐会红 李霞 +4 位作者 高新培 褚智君 付连浩 周航 缴万里 《中国医院用药评价与分析》 2024年第10期1196-1199,共4页
目的:了解左心室血栓(LVT)患者抗栓治疗方案现状,并分析口服抗凝血药使用情况和LVT患者的临床转归情况,为LVT的治疗提供参考。方法:纳入2018年5月至2023年9月该院电子病历系统中诊断为LVT的患者,回顾性分析患者的抗凝血药使用情况,探讨... 目的:了解左心室血栓(LVT)患者抗栓治疗方案现状,并分析口服抗凝血药使用情况和LVT患者的临床转归情况,为LVT的治疗提供参考。方法:纳入2018年5月至2023年9月该院电子病历系统中诊断为LVT的患者,回顾性分析患者的抗凝血药使用情况,探讨抗凝治疗与非抗凝治疗、新型口服抗凝血药(NOAC)与华法林的血栓消退情况、血栓栓塞及出血事件发生情况。结果:共纳入156例患者,120例(占76.9%)患者接受抗凝治疗,其中接受NOAC治疗的患者为87例(占55.8%),接受华法林治疗的患者为33例(占21.2%)。抗凝组患者血栓栓塞事件发生率明显低于非抗凝组[5.0%(6/120)vs.16.7%(6/36),P=0.032],且未升高出血事件发生率[13.3%(16/120)vs.25.0%(9/36),P=0.094];NOAC组与华法林组患者血栓栓塞、出血事件发生率的差异均无统计学意义(P>0.05)。进一步分析106例有影像学资料患者的血栓转归情况,72例(占67.9%)患者的左心室血栓完全消退。抗凝组患者血栓消退率明显高于非抗凝组[72.4%(63/87)vs.47.4%(9/19),P=0.034],且血栓消退中位时间更短[48.0(32.0,120.0)d vs.(167.4±113.0)d,P=0.035],差异均有统计学意义。与华法林组比较,NOAC组患者血栓消退率相似,差异无统计学意义[71.4%(45/63)vs.75.0%(18/24),P=0.739];NOAC组患者血栓消退速度更快,差异有统计学意义[43.0(32.0,85.0)d vs.106.0(32.8,239.8)d,P=0.049]。结论:抗凝治疗可改善LVT患者血栓消退,减少血栓栓塞事件且不增加出血风险,但该院抗凝治疗比例仍有待提高。NOAC可考虑作为华法林的替代治疗,尤其是对华法林不耐受的患者。 展开更多
关键词 左心室血栓 抗凝 口服抗凝血药 新型口服抗凝血药 非维生素K拮抗剂
下载PDF
医院药房口服单剂量调配模式的探索与实践
20
作者 杨丽萍 商然 +3 位作者 王海玲 杨帆 刘静 赵志刚 《中国药事》 CAS 2024年第6期724-730,共7页
目的:缩短口服单剂量调配时间,提高工作效率。方法:分析既往单剂量分包模式的不足,从设备、软件、流程等方面改进,包括设计智能棋盘式摆药盘、优化合并备用药槽及使用三备用药槽。比较口服单剂量调配模式改进前后的工作效率。结果:使用... 目的:缩短口服单剂量调配时间,提高工作效率。方法:分析既往单剂量分包模式的不足,从设备、软件、流程等方面改进,包括设计智能棋盘式摆药盘、优化合并备用药槽及使用三备用药槽。比较口服单剂量调配模式改进前后的工作效率。结果:使用智能棋盘式摆药盘后,每条口服医嘱的调配时间从之前的(5.4±0.16)s缩短至(3.5±0.27)s,药师调配速度显著提高(P<0.05)。与改进前的全自动摆药模式相较,改进后平均每包调配时间缩短了24.72%~56.39%,平均每包调配时长显著短于改进前(P<0.05)。与人工摆药模式相较,改进前的全自动摆药模式调配药师从3名缩减至2名,每日人均调配医嘱条数提高至2848.90±153.21,显著高于人工摆药模式(P<0.05),工作效率提升了114.82%;改进后的全自动摆药模式每日人均调配医嘱条数提高至3671.90±56.48,显著高于人工摆药模式(P<0.05),效率提升了176.87%。结论:通过对我院既往单剂量调配模式的改进,工作效率显著提高。 展开更多
关键词 口服单剂量 智能棋盘式摆药盘 三备用药槽 调配模式
下载PDF
上一页 1 2 80 下一页 到第
使用帮助 返回顶部